潘普洛納生物科技（香港）有限公司

Our lead program is a clinical-stage drug candidate targeting autoimmune diseases, built on a novel, differentiated mechanism of action. It has successfully secured IND clearances in both China and the U.S., validating our robust translational expertise and global regulatory readiness, while addressing substantial unmet medical needs for patients worldwide.
Complementing our pipeline, we have established a proprietary ASTRIDE platform that integrates rational degrader design with a rigorous ubiquitination assessment system. Highly scalable and versatile, this platform enables rapid expansion across a wide range of targets, fueling the advancement of a diversified pipeline spanning first-in-class and best-in-class therapeutic modalities.
Collectively, our clinical assets and foundational platform constitute a distinctive, scalable innovation engine. This integrated strategy drives continuous pipeline generation and progression, positioning us to deliver transformative therapies and achieve sustainable, long-term growth in the global biotech landscape.